CV Therapeutics seeking partner for ranolazine SR Phase III angina trials.
CV THERAPEUTICS SEEKING PARTNER TO SUPPORT RANOLAZINE SR PHASE III TRIALS for angina, the company said in its recent initial public offering prospectus. "The company's clinical development plan for ranolazine assumes that Phase I data and several Phase II angina trials with [immediate-release] ranolazine combined with Phase I data and safety and tolerability data from a pilot Phase II trial for intermittent claudication with ranolazine [sustained release] will be accepted by the FDA to initiate Phase III trials with ranolazine SR," the prospectus cautions.
You may also be interested in...
CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011